Cytogenetic and molecular genetic evolution of chronic myeloid leukemia

Acta Haematologica
Bertil JohanssonFelix Mitelman

Abstract

Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. In 2-10% of the cases, this chimeric gene is generated by variant rearrangements, involving 9q34, 22q11, and one or several other genomic regions. All chromosomes have been described as participating in these variants, but there is a marked breakpoint clustering to chromosome bands 1p36, 3p21, 5q13, 6p21, 9q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12, and 22q13. Despite their genetically complex nature, available data indicate that variant rearrangements do not confer any specific phenotypic or prognostic impact as compared to CML with a standard Ph chromosome. In most instances, the t(9;22), or a variant thereof, is the sole chromosomal anomaly during the chronic phase (CP) of the disease, whereas additional genetic changes are demonstrable in 60-80% of cases in blast crisis (BC). The secondary chromosomal aberrations are clearly nonrandom, with the most common chromosomal abnormalities being +8 (34% of cases with additional changes), +Ph (30%), i(17q) (20%), +19 (13%), -Y (8% of ma...Continue Reading

Citations

May 12, 2005·Cancer Immunology, Immunotherapy : CII·Yi ZengEmmanuel Katsanis
Oct 29, 2011·Cancer Immunology, Immunotherapy : CII·Michal Smahel
Jun 17, 2008·Annals of Hematology·Francesco AlbanoGiorgina Specchia
May 1, 2007·Current Hematologic Malignancy Reports·Tomasz Skorski
Feb 14, 2012·Current Hematologic Malignancy Reports·Tomasz Skorski
Mar 20, 2012·Current Hematologic Malignancy Reports·N MuvarakF V Rassool
Aug 23, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M Dolores DelgadoJavier León
Mar 27, 2009·International Journal of Hematology·Marija Denčić-FeketeMirjana Gotić
Feb 22, 2005·Cancer Genetics and Cytogenetics·Juan Pablo Meza EspinozaJuan Ramón González García
Jan 22, 2004·Cancer Genetics and Cytogenetics·Juan Pablo Meza EspinozaJuan Ramón González García
Sep 16, 2003·Blood Cells, Molecules & Diseases·Silvia BuonamiciGiuseppina Nucifora
Mar 16, 2007·Nature Reviews. Cancer·Felix MitelmanFredrik Mertens
May 25, 2007·Nature Reviews. Cancer·Junia V Melo, David J Barnes
Jan 11, 2007·Bone Marrow Transplantation·K KarrmanB Johansson
Jun 5, 2003·Seminars in Hematology·Michael W N Deininger
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators
Oct 10, 2003·The New England Journal of Medicine·John M Goldman, Junia V Melo
Nov 15, 2007·Cytogenetic and Genome Research·C J YeH H Q Heng
Jul 2, 2010·The Journal of Clinical Investigation·Danilo PerrottiTomasz Skorski
Jul 23, 2011·Genes & Cancer·M Dolores Delgado, Javier León

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.